FONT-SIZE Plus   Neg

AVI BioPharma Gets FDA Approval To Proceed With AVI-7288 To Treat Marburg Virus

AVI BioPharma, Inc. (AVII) Tuesday announced that the U.S Food and Drug Administration, or the FDA, has granted approval to the company to proceed with a single oligomer, AVI-7288, in studies in both humans and non-human primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection.

The company stated that AVI-7288 is one of two components that make up AVI-6003.

The company further added that it will proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies planned to characterize the safety, tolerability and pharmacokinetics of multiple doses of the drug in healthy adult volunteers.

"While we have not seen any toxicity in humans to date with AVI-6003, by removing AVI-7287 we have a simpler development path and may improve the therapeutic window by evaluating a single action agent," said Chris Garabedian, president and CEO of AVI BioPharma. "We are pleased to be able to explore this single oligomer as a potentially safe and effective treatment against this lethal hemorrhagic fever virus."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer goods giant Procter & Gamble Co. on Tuesday reported a 4 percent increase in profit for the first quarter from last year on a slight decline in sales. However, both revenue and core earnings per share for the quarter beat analysts' estimates. In addition, the company affirmed its financial outlook for fiscal 2017. Merck & Co. Inc. (MRK) reported a profit for the third-quarter that increased about 20 percent, while quarterly worldwide sales grew 5 percent. The company raised its full-year 2016 outlook. Drug maker Eli Lilly and Co. reported Tuesday lower profit in its third quarter, despite higher revenues. Adjusted earnings per share and top line missed analysts' estimates. Further, for fiscal 2016, the company trimmed its forecast for reported earnings, while maintained adjusted earnings view, and raised revenue forecast.
comments powered by Disqus
Follow RTT